LONG-acting opioids may
increase the risk of hypogonadism
(low testosterone) in men when
compared to those taking
short-acting opioids, according to a
new study.
Presented at the American
Academy of Pain Medicine’s 28th
Annual Meeting, the small
retrospective study involved 81
men aged 18-80 who were
referred by primary care to the
tertiary pain clinic.
The men were on a stable dose
of daily opioids for at least 90 days,
and none had a previous diagnosis
of hypogonadism.
The study found that 57% of men
were hypogonadal overall, but that
74% of those on long-acting
opioids were hypogonadal,
compared to 34% of those on
short term medications.The above article was sent to subscribers in Pharmacy Daily's issue from 27 Feb 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 Feb 12
DEMENTIA Australia has appointed comedian Geraldine Hickey (pictured) as its newest Ambassador, coinciding with the Melbourne Memory Walk & Jog event taking place this Sun.
NEW research from the Monash Addiction Research Centre has highlighted a critical shortfall in the availability of Naloxone, a life-saving medication that reverses opioid overdoses, across community pharmacies in Australia’s most populous states.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.